个人中心 - 老虎社区

Ciboy

IP属地：未知

帖子 · 7帖子 · 7
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- CiboyCiboy
  ·2021-12-23
  Isit a buy?
  非常抱歉，此主贴已删除
  2,344 评论
  1
  分享
  举报
- CiboyCiboy
  ·2021-10-28
  Nice one
  非常抱歉，此主贴已删除
  2,820 1
  2
  分享
  举报
- CiboyCiboy
  ·2021-09-11
  Good buy?
  Why Novavax Stock Slipped Thursday<blockquote>为什么 Novavax 股价周四下跌</blockquote>
  (Update: Sept 10, 2021 at 04:14 a.m. ET) Authorization of the company's COVID-19 vaccine in India a
  Why Novavax Stock Slipped Thursday<blockquote>为什么 Novavax 股价周四下跌</blockquote>
  1,745 评论
  2
  分享
  举报
- CiboyCiboy
  ·2021-08-23
  Thumbs up. Like please
  Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和 BioNTech SE 股价在盘前交易中飙升</blockquote>
  Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval
  Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和 BioNTech SE 股价在盘前交易中飙升</blockquote>
  1,883 1
  2
  分享
  举报
- CiboyCiboy
  ·2021-08-21
  Good article
  非常抱歉，此主贴已删除
  1,565 评论
  2
  分享
  举报
- CiboyCiboy
  ·2021-08-20
  The 3 Rs.
  1,733 评论
  点赞
  分享
  举报
- CiboyCiboy
  ·2021-06-08
  Like and comment
  非常抱歉，此主贴已删除
  1,250 2
  5
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582794558746184","uuid":"3582794558746184","gmtCreate":1619707409658,"gmtModify":1619707409658,"name":"Ciboy","pinyin":"ciboy","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"60.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":691518254,"gmtCreate":1640220048801,"gmtModify":1640220048801,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"title":"","htmlText":"Isit a buy?","listText":"Isit a buy?","text":"Isit a buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691518254","repostId":"1116093171","repostType":4,"isVote":1,"tweetType":1,"viewCount":2344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854001639,"gmtCreate":1635408427135,"gmtModify":1635408427135,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"title":"","htmlText":"Nice one","listText":"Nice one","text":"Nice one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854001639","repostId":"1148392141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":881119079,"gmtCreate":1631316218291,"gmtModify":1632883268821,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"title":"","htmlText":"Good buy?","listText":"Good buy?","text":"Good buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881119079","repostId":"1158877090","repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://www.laohunote.com/m/news/1158877090?lang=zh_CN&edition=full","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday<blockquote>为什么 Novavax 股价周四下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间 2021 年 9 月 10 日凌晨 04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司新冠肺炎疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求提供 Novavax 的 COVID-19 候选疫苗的额外数据，然后才能授予紧急使用授权。</li><li>印度疫苗的EUA最初预计在10月份，但现在将被推迟。</li><li>这一延迟对 Novavax 来说并不是一个巨大的打击，因为该公司在发达市场拥有更大的机会。</li></ul><b>发生了什么事</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>股份<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>截至下午 3:25，下跌 2.6%。美国东部时间周四。这一下降是在一份报告之后发生的<i>经济时报</i>印度政府已要求 Novavax 的合作伙伴印度血清研究所 (SII) 提供 COVID-19 候选疫苗 NVX-CoV2373（在印度称为 Covovax）的更多数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII 于 8 月在印度为 Covovax 申请了紧急使用授权 (EUA)。该提交基于国际临床研究的数据。据报道，印度药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII 可能要到下个月才能提交 Covovax 在印度的临床研究数据。SII 首席执行官 Adar Poonawalla 在 8 月份表示，他的组织希望 COVID-19 疫苗能够于 10 月在印度针对成人推出，并于 2022 年第一季度针对儿童推出。这个时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对 Novavax 来说并不是一个巨大的打击，疫苗库存下降相对较小就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax 预计将在未来几周内在英国为 NVX-CoV2373 申请 EUA。澳大利亚、新西兰和欧盟应尽快提交申请。该公司仍有望在 2021 年第四季度申请美国 EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax 在盘前交易中下跌超过 2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday<blockquote>为什么 Novavax 股价周四下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday<blockquote>为什么 Novavax 股价周四下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-10 15:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间 2021 年 9 月 10 日凌晨 04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司新冠肺炎疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求提供 Novavax 的 COVID-19 候选疫苗的额外数据，然后才能授予紧急使用授权。</li><li>印度疫苗的EUA最初预计在10月份，但现在将被推迟。</li><li>这一延迟对 Novavax 来说并不是一个巨大的打击，因为该公司在发达市场拥有更大的机会。</li></ul><b>发生了什么事</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>股份<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>截至下午 3:25，下跌 2.6%。美国东部时间周四。这一下降是在一份报告之后发生的<i>经济时报</i>印度政府已要求 Novavax 的合作伙伴印度血清研究所 (SII) 提供 COVID-19 候选疫苗 NVX-CoV2373（在印度称为 Covovax）的更多数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII 于 8 月在印度为 Covovax 申请了紧急使用授权 (EUA)。该提交基于国际临床研究的数据。据报道，印度药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII 可能要到下个月才能提交 Covovax 在印度的临床研究数据。SII 首席执行官 Adar Poonawalla 在 8 月份表示，他的组织希望 COVID-19 疫苗能够于 10 月在印度针对成人推出，并于 2022 年第一季度针对儿童推出。这个时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对 Novavax 来说并不是一个巨大的打击，疫苗库存下降相对较小就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax 预计将在未来几周内在英国为 NVX-CoV2373 申请 EUA。澳大利亚、新西兰和欧盟应尽快提交申请。该公司仍有望在 2021 年第四季度申请美国 EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax 在盘前交易中下跌超过 2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835841840,"gmtCreate":1629706755480,"gmtModify":1633683047572,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"title":"","htmlText":"Thumbs up. Like please","listText":"Thumbs up. Like please","text":"Thumbs up. Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835841840","repostId":"1104804215","repostType":4,"repost":{"id":"1104804215","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706373,"share":"https://www.laohunote.com/m/news/1104804215?lang=zh_CN&edition=full","pubTime":"2021-08-23 16:12","market":"us","language":"en","title":"Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和 BioNTech SE 股价在盘前交易中飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104804215","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval","content":"<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p><p><blockquote>辉瑞和 BioNTech SE 股价在盘前交易中飙升。F.D.A。据《纽约时报》报道，辉瑞公司的目标是在周一全面批准辉瑞公司的 Covid 疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p><p><blockquote>据熟悉美国食品和药物管理局计划的人士透露，美国食品和药物管理局正在推动在周一批准辉瑞-BioNTech公司的两剂Covid-19疫苗，进一步加快了疫苗许可的早期时间表。</blockquote></p><p> Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p><p><blockquote>监管机构正在努力在周五之前完成这一流程，但仍在与该公司进行大量的文书工作和谈判。熟悉该计划的人士没有被授权公开谈论该计划，他们警告说，如果审查的某些部分需要更多时间，批准可能会推迟到周一之后。</blockquote></p><p> An F.D.A. spokeswoman declined to comment.</p><p><blockquote>F.D.A。女发言人拒绝置评。</blockquote></p><p> The agency had recently set an unofficial deadline for approval of around Labor Day.</p><p><blockquote>该机构最近设定了一个非官方的批准截止日期，大约在劳动节前后。</blockquote></p><p> The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p><p><blockquote>该批准预计将为公共和私人组织的一系列疫苗接种要求铺平道路，这些组织正在等待最终的监管行动，然后再实施授权。联邦和州卫生官员也希望获得批准的疫苗能够吸引一些美国人的兴趣，他们一直在犹豫是否要接种仅授权紧急使用的疫苗，最近的民意调查表明了这种现象。</blockquote></p><p> Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p><p><blockquote>一旦疫苗获得完全批准，一些大学和医院预计将强制接种疫苗。五角大楼本月表示，计划 “不迟于 ”下月中旬强制全国 130 万现役军人接种 Covid 疫苗，如果美国食品和药物管理局批准，则更早。早点行动。</blockquote></p><p> Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p><p><blockquote>一旦获得批准，辉瑞-BioNTech计划迅速向F.D.A。批准第三剂作为加强注射。拜登政府周三宣布，从9月20日开始，完全接种疫苗的成年人应该准备在接种第二剂疫苗八个月后接种加强针。辉瑞公司预计将于下周完成提交数据，该数据显示第三剂疫苗是安全有效的。</blockquote></p><p> The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p><p><blockquote>F.D.A。上周，辉瑞-BioNTech 和 Moderna 疫苗的授权更新，允许一些免疫功能低下的人接种第三剂疫苗，这一决定得到了美国疾病控制和预防中心的支持。</blockquote></p><p> Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p><p><blockquote>监管机构仍在审查 Moderna 的冠状病毒疫苗全面批准申请，辉瑞-BioNTech 的申请至少可能在几周后做出决定。Moderna 计划提交数据以支持 9 月份的加强注射。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和 BioNTech SE 股价在盘前交易中飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和 BioNTech SE 股价在盘前交易中飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-23 16:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p><p><blockquote>辉瑞和 BioNTech SE 股价在盘前交易中飙升。F.D.A。据《纽约时报》报道，辉瑞公司的目标是在周一全面批准辉瑞公司的 Covid 疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p><p><blockquote>据熟悉美国食品和药物管理局计划的人士透露，美国食品和药物管理局正在推动在周一批准辉瑞-BioNTech公司的两剂Covid-19疫苗，进一步加快了疫苗许可的早期时间表。</blockquote></p><p> Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p><p><blockquote>监管机构正在努力在周五之前完成这一流程，但仍在与该公司进行大量的文书工作和谈判。熟悉该计划的人士没有被授权公开谈论该计划，他们警告说，如果审查的某些部分需要更多时间，批准可能会推迟到周一之后。</blockquote></p><p> An F.D.A. spokeswoman declined to comment.</p><p><blockquote>F.D.A。女发言人拒绝置评。</blockquote></p><p> The agency had recently set an unofficial deadline for approval of around Labor Day.</p><p><blockquote>该机构最近设定了一个非官方的批准截止日期，大约在劳动节前后。</blockquote></p><p> The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p><p><blockquote>该批准预计将为公共和私人组织的一系列疫苗接种要求铺平道路，这些组织正在等待最终的监管行动，然后再实施授权。联邦和州卫生官员也希望获得批准的疫苗能够吸引一些美国人的兴趣，他们一直在犹豫是否要接种仅授权紧急使用的疫苗，最近的民意调查表明了这种现象。</blockquote></p><p> Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p><p><blockquote>一旦疫苗获得完全批准，一些大学和医院预计将强制接种疫苗。五角大楼本月表示，计划 “不迟于 ”下月中旬强制全国 130 万现役军人接种 Covid 疫苗，如果美国食品和药物管理局批准，则更早。早点行动。</blockquote></p><p> Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p><p><blockquote>一旦获得批准，辉瑞-BioNTech计划迅速向F.D.A。批准第三剂作为加强注射。拜登政府周三宣布，从9月20日开始，完全接种疫苗的成年人应该准备在接种第二剂疫苗八个月后接种加强针。辉瑞公司预计将于下周完成提交数据，该数据显示第三剂疫苗是安全有效的。</blockquote></p><p> The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p><p><blockquote>F.D.A。上周，辉瑞-BioNTech 和 Moderna 疫苗的授权更新，允许一些免疫功能低下的人接种第三剂疫苗，这一决定得到了美国疾病控制和预防中心的支持。</blockquote></p><p> Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p><p><blockquote>监管机构仍在审查 Moderna 的冠状病毒疫苗全面批准申请，辉瑞-BioNTech 的申请至少可能在几周后做出决定。Moderna 计划提交数据以支持 9 月份的加强注射。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104804215","content_text":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.\n\nThe Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.\nRegulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.\nAn F.D.A. spokeswoman declined to comment.\nThe agency had recently set an unofficial deadline for approval of around Labor Day.\nThe approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.\nSome universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.\nOnce it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.\nThe F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.\nRegulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836511851,"gmtCreate":1629506796773,"gmtModify":1633684407315,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"title":"","htmlText":"Good article","listText":"Good article","text":"Good article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/836511851","repostId":"2160176501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838259531,"gmtCreate":1629415328623,"gmtModify":1633685078591,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"title":"","htmlText":"The 3 Rs.","listText":"The 3 Rs.","text":"The 3 Rs.","images":[{"img":"https://static.tigerbbs.com/2b73a296bec84f92723b409fc422943f","width":"1440","height":"1835"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/838259531","isVote":1,"tweetType":1,"viewCount":1733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114747983,"gmtCreate":1623108223142,"gmtModify":1634036977719,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"title":"","htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114747983","repostId":"2141342255","repostType":4,"isVote":1,"tweetType":1,"viewCount":1250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}